BTIG Sticks to Its Buy Rating for Zimmer Biomet Holdings (ZBH)
BTIG analyst Ryan Zimmerman maintained a Buy rating on Zimmer Biomet Holdings on February 18 and set a price target of $112.00.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Zimmerman is an analyst with an average return of -0.6% and a 40.80% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Stryker, Zimmer Biomet Holdings, and Organogenesis Holdings.
In addition to BTIG, Zimmer Biomet Holdings also received a Buy from TipRanks – PerPlexity’s PerPlexity Medical – Devices in a report issued on February 11. However, today, William Blair initiated coverage with a Hold rating on Zimmer Biomet Holdings (NYSE: ZBH).
Based on Zimmer Biomet Holdings’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2.24 billion and a net profit of $139.5 million. In comparison, last year the company earned a revenue of $2.02 billion and had a net profit of $239.5 million
Read More on ZBH:
Disclaimer & DisclosureReport an Issue
- Walmart downgraded, Etsy upgraded: Wall Street’s top analyst calls
- Zimmer Biomet initiated with a Market Perform at William Blair
- Zimmer Biomet’s New Stemless Shoulder Study Signals Strategic Push in Joint Reconstruction
- Zimmer Biomet price target lowered to $100 from $104 at Barclays
- Zimmer Biomet participates in a conference call with JPMorgan
